Senzime AB (publ)
Senzime AB (publ) develops and commercializes automated blood culture systems for the detection of microorganisms in clinical microbiology laboratories.
Business. Senzime AB (publ) (SEZI.ST) is a healthcare company operating within the Medical Equipment, Supplies & Distribution industry. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Senzime AB (publ) (SEZI.ST) is a healthcare company operating within the Medical Equipment, Supplies & Distribution industry. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Senzime operates with a strong equity base of 304.5 million SEK and a low debt-to-equity ratio of 0.05, indicating a conservative capital structure. The company's liquidity position is characterized as medium risk, with a current ratio of 3.68, suggesting adequate short-term liquidity to cover obligations. However, the negative net cash position after subtracting total debt raises concerns about immediate liquidity flexibility.
Profitability metrics reveal significant challenges, with a return on equity of -45.14% and return on assets of -37.03%, both well below industry norms for medical equipment firms. The company reported a net loss of 137.4 million SEK and an operating loss of 122.6 million SEK, with a gross margin of 33.3% that fails to offset operating costs.
Geographically, Senzime's revenue is concentrated in its domestic market, with no disclosed international revenue segments. The company's product portfolio is focused on automated blood culture systems, with no material diversification across therapeutic areas or customer types. This concentration increases exposure to local regulatory changes and reimbursement pressures.
Looking ahead, revenue is projected to grow from 104.0 million SEK to 176.0 million SEK, representing a 69.2% increase. However, this growth is not reflected in operating performance, as analysts expect continued losses with an estimated EPS of -0.40 SEK versus -0.93 SEK in the prior period. The company's free cash flow remains negative at -132.0 million SEK, with capital expenditures of -18.1 million SEK.
Risk factors include the company's reliance on a narrow product portfolio and its history of operating losses. The risk assessment indicates low dilution potential, but the negative operating cash flow and free cash flow raise liquidity concerns. No material dilutive events were identified in recent filings, and the company has not disclosed any shelf registration or ATM programs.
Recent filings show continued investment in R&D and product development, with no material changes in strategic direction. The company's price target of 9.50 SEK implies a 110% upside from the current market price of 4.53 SEK, but this is based on analysts' expectations of revenue growth without corresponding improvements in profitability.
- Senzime maintains a conservative capital structure with low leverage but faces liquidity risks due to negative net cash.
- The company's profitability metrics are severely negative, with ROE and ROA well below industry norms.
- Revenue growth is projected at 69.2%, but this is not translating into improved operating performance.
- The company's product portfolio is narrowly focused, increasing exposure to market-specific risks.
- Analysts expect continued losses despite revenue growth, with a significant price target upside based on revenue expectations.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,40 |
| Revenue | —no estimate | —no estimate | 176,0M SEK |
| Operating income | —no estimate | —no estimate | -69,0M SEK |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Senzime AB (publ) Market data — financials · 2026-05-29
- Senzime AB (publ) Market data — analyst estimates · 2026-05-29
- Senzime AB (publ) Market data — ESG · 2026-05-29